Acquistion of an inFlux GMP cell sorter.

描述（由申请人提供）：对适用于纯化临床前和临床用途的原代人细胞的荧光激活细胞分选仪的需求日益增长。这提出了超出常规研究细胞分选中遇到的技术挑战。主要关注的是降低样品污染的风险，同时保护操作人员免受潜在的生物危害性气溶胶的影响。目前在华盛顿大学或附近的圣路易斯大学健康科学中心的校园里还没有适合分选原代人类细胞的仪器。该提案要求提供资金购买inFlux细胞分选仪（Cytopeia，Inc.）。该仪器具有几个设计特点，使其非常适合分选人类细胞。inFlux将被纳入由PI指导的华盛顿大学Alvin J. Siteman癌症中心（一个NCI指定的癌症中心）内的成功细胞分选核心设施。几个主要用户提出的使用inFlux生产临床级细胞产品的建议将受益于与细胞分选核心相邻的最先进的“良好生产规范”（GMP）设施。建设650平方米。英尺inFlux的空间和支持系统已经完成。inFlux的持续运营和服务费用将由Siteman癌症中心提供，并由用户费用抵消。一个由Siteman癌症中心高级领导组成的咨询委员会将监督inFlux的管理和利用。主要用户均为具有重要细胞计数专业知识的知名和受资助科学家，第一年将占100%的利用率，随后几年至少占75%。剩余的时间将分配给华盛顿大学和圣路易斯大学的其他研究人员，优先考虑Siteman癌症中心的成员。该仪器将为华盛顿大学的许多资助项目提供附加值，这些项目在2002年从NIH获得的总奖金中总计超过3.28亿美元，在美国医学中心中排名第三。

DESCRIPTION (provided by applicant): There is a growing need for fluorescence-activated cell sorters suitable for purifying primary human cells for preclinical and clinical uses. This poses technical challenges above and beyond those encountered in routine research cell sorting. The primary concerns are reducing the risk of sample contamination while protecting operators from potentially biohazardous aerosols. There are currently no instruments suitable for sorting primary human cells at Washington University or the nearby campus of St. Louis University Health Sciences Center. This proposal requests funds to purchase the inFlux cell sorter (Cytopeia, Inc.). This instrument has several design features that make it well-adapted to sorting human cells. The inFlux will be incorporated into a successful cell sorting core facility directed by the PI within the Alvin J. Siteman Cancer Center at Washington University, an NCI-designated Cancer Center. The proposal by several of the Major Users to use the inFlux for generation of clinical grade cellular products will benefit from a state-of-the-art "Good Manufacturing Practices" (GMP) facility that is contiguous with the cell sorting core. Construction of the 650 sq. ft. space and support systems for the inFlux have been completed. Ongoing costs for operation and servicing of the inFlux will be provided by the Siteman Cancer Center and offset by user fees. An advisory committee consisting of senior leadership from the Siteman Cancer Center will oversee management and utilization of the inFlux. The Major Users, all established and funded scientists with significant cytometry expertise, will account for 100% of utilization in year one and a minimum of 75% in subsequent years. The remaining hours will be allocated to other investigators at Washington University ant St. Louis University, with priority given to members of the Siteman Cancer Center. This instrument will provide added value for many funded projects at Washington University that collectively accounted for over $328M in total awards from the NIH in 2002, placing it third among medical centers in the United States.